NCM · Biotechnology

ONCO (ONCO) Stock

$0.81 -1.89% NCM: ONCO Healthcare

Valuation

MetricValue
Price$0.81
Market Cap$270931
P/E Ratio-0.02
P/B Ratio0.02
P/S Ratio0.51
EPS (TTM)$-4.73
52-Week High$270.00
52-Week Low$0.77
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-87.50%
ROA-56.00%
ROCE-37.50%
Gross Margin-600.00%
Operating Margin-600.00%
Net Margin-13.20%
Debt/Equity0.02
Current Ratio0.67

Annual Financials (USD)

Metric20212022202320242025
Revenue$0$0$0$3.0M$1.0M
Operating Profit$-3.0M$-13.0M$-36.0M$-56.0M$-6.0M
Net Profit$-3.0M$-13.0M$-37.0M$-59.0M$-14.0M
EPS$-0.09$-0.31$-25.03$-520.93$-4.73
Op Margin——-61634.5%-2238.0%-778.2%

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$3.0M$26.0M$88.0M$28.0M$25.0M
Total Liabilities$2.0M$4.0M$86.0M$19.0M$9.0M
Cash$2.0M$26.0M$5.0M$1.0M$5.0M
Borrowings$0$0$10.0M$9.0M$0

Latest News

Onconetix Highlights Realbotix Partnership with Bloom Services to Launch UK Pilot Using Humanoid Robots to Combat Elderly Social Isolation GlobeNewswire · Jul 7, 2026 Onconetix Highlights Realbotix’s Launch of Humanoid Robot and AI Teachers Assistant Pilot Program in New York State School District GlobeNewswire · Jun 24, 2026 BC-Most Active Stocks Associated Press · May 19, 2026 Onconetix, Inc. Announces 1-for-10 Reverse Stock Split GlobeNewswire · May 19, 2026 Onconetix Reports Q1 2026 Progress at Proteomedix AG, Including Two New Peer-Reviewed Publications and Initiation of U.S. Validation Study GlobeNewswire · May 13, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-2.0M$-9.0M$-14.0M$-10.0M$-10.0M
Investing Cash Flow$0$0$-9.0M$0$0
Financing Cash Flow$0$-2.0M$0$0$0
Net Cash Flow$-2.0M$24.0M$-21.0M$-4.0M$5.0M
Free Cash Flow$-2.0M$-9.0M$-14.0M$-11.0M$-10.0M

Valuation & Return Ratios

MetricValue
PEG Ratio—
EV / EBITDA—
FCF Yield-2600.24%
Quick Ratio1.37
Interest Coverage-6.00
Return 1Y-99.66%
Return 3Y-100.00%
Return 5Y—

Ownership

Insiders Held0.18%
Institutions Held0.06%
Institutions Float Held0.06%

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
AZTR $0.14 +0.80% -0.09 $1.49M 0.00%
ENVB $1.34 +3.88% -0.04 $799996 0.00%
INDP $1.39 -3.82% -0.06 $2.43M 0.00%
JSPR $0.63 +1.48% -0.21 $10.24M 0.00%
PTIXProtagenic Therapeutics, Inc. $0.26 +18.18% -0.08 $470654 0.00%

About ONCO

ONCO is led by CEO David Allan White, employs 12 people, headquartered in US, publicly traded since 2022.

ONCO stock trades at $0.81 with a market capitalization of $270931. The stock is valued at a price-to-earnings (P/E) ratio of -0.02, price-to-book of 0.02, price-to-sales of 0.51. Over the past 52 weeks the stock has ranged between $0.77 and $270.00, and currently trades 99.7% below its 52-week high.

On profitability, ONCO generates a return on equity (ROE) of -87.50%, return on capital employed of -37.50%, an operating margin of -600.00%, a net profit margin of -13.20%.

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksAll stock screens
Run Stock Screener Investing Guides